Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.

A committee report found the weight loss drug is offered for less than $100 in some European countries, compared to monthly prices exceeding $1,000 in the U.S.

In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D) costs, payments, milestone fees, and royalties, with the explicit aim of bolstering its cardiometabolic disease therapy pipeline via as-yet-unexplored therapeutic modalities.

Novo Nordisk CEO Lars Fruergaard Jørgensen testified before the Senate Health, Education, Labor and Pension committee on Tuesday.

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for brand-name prescriptions.

The head of Ozempic manufacturer Novo Nordisk on Tuesday defended the high price of the company’s highly sought-after obesity and Type 2 diabetes drugs, blaming pharma middlemen and insurers for the price.

For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their health.

Novo Nordisk CEO Lars Fruergaard Jørgensen faces a Senate hearing led by Bernie Sanders over the high cost of Ozempic and Wegovy, as U.S. lawmakers push for drug price reductions.

Chairman of the Senate Committee on Health, Education, Labor, and Pensions (HELP), today led the committee in a hearing to examine why Novo Nordisk charges the American people the highest prices in the world for its lifesaving drugs,

During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company's high prices for its blockbuster drugs Ozempic and Wegovy.